12V Stock Overview
Operates as a diagnostics company in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Veracyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$31.40 |
| 52 Week High | US$31.80 |
| 52 Week Low | US$17.50 |
| Beta | 1.66 |
| 11 Month Change | 5.37% |
| 3 Month Change | 65.26% |
| 1 Year Change | 38.94% |
| 33 Year Change | -26.98% |
| 5 Year Change | 48.11% |
| Change since IPO | 278.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| 12V | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.6% | -0.4% | -1.8% |
| 1Y | 38.9% | -15.4% | 13.6% |
Return vs Industry: 12V exceeded the German Biotechs industry which returned -15.4% over the past year.
Return vs Market: 12V exceeded the German Market which returned 13.6% over the past year.
Price Volatility
| 12V volatility | |
|---|---|
| 12V Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 12V's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 12V's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 815 | Marc Stapley | www.veracyte.com |
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test.
Veracyte, Inc. Fundamentals Summary
| 12V fundamental statistics | |
|---|---|
| Market cap | €2.42b |
| Earnings (TTM) | -€49.69m |
| Revenue (TTM) | €367.37m |
6.7x
P/S Ratio-49.7x
P/E RatioIs 12V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 12V income statement (TTM) | |
|---|---|
| Revenue | US$399.58m |
| Cost of Revenue | US$129.17m |
| Gross Profit | US$270.41m |
| Other Expenses | US$324.45m |
| Earnings | -US$54.04m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 06, 2024
| Earnings per share (EPS) | -0.70 |
| Gross Margin | 67.67% |
| Net Profit Margin | -13.52% |
| Debt/Equity Ratio | 0% |
How did 12V perform over the long term?
See historical performance and comparison